Related Experiment Video

Updated: May 3, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

974

Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells

Mutaz Mohammed Nur1, Stephen Finn, John V Reynolds

  • 1Department of Histopathology, Waterford Regional Hospital, Waterford, Ireland.

Expert Review of Anticancer Therapy
|February 14, 2014
PubMed

Insights

Researchers identified TIMP-4 as a promising molecular target for esophageal cancer treatment. Its expression is high in tumors, low in normal tissue, and unaffected by neoadjuvant chemotherapy, suggesting its potential as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Targeting specific molecules and pathways is a key strategy in cancer treatment.
  • Esophageal cancer treatment often involves neoadjuvant chemotherapy.
  • Understanding protein expression in tumors is crucial for developing targeted therapies.

Purpose of the Study:

  • To review a study examining the expression of five proteins in esophageal cancer.
  • To compare protein expression in cancerous versus adjacent normal tissues.
  • To assess the impact of neoadjuvant chemotherapy on protein expression levels.

Main Methods:

  • Analysis of five specific protein expression levels in esophageal cancer tissues.
  • Comparison of protein expression between tumor and adjacent normal tissues.
  • Evaluation of protein expression changes following neoadjuvant chemotherapy.

Main Results:

  • TIMP-4 (Tissue Inhibitor of Metalloproteinases-4) was identified as a highly promising target.
  • TIMP-4 showed significantly higher expression in esophageal tumors compared to normal tissues.
  • High TIMP-4 expression levels were maintained even after neoadjuvant chemotherapy treatment.

Conclusions:

  • TIMP-4 represents a potential therapeutic target for esophageal cancer.
  • Its selective expression in tumors and resistance to neoadjuvant chemotherapy support its candidacy.
  • Further investigation into TIMP-4 as a treatment target is warranted.

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

13.1K
Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues05:57

Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues

Published on: May 30, 2025

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81